We use cookies to ensure that the website works as intended and to collect statistics on its use so that we can improve your web site experience.


Aker BioMarine appoints SVP Investor Relations

Back to news

Aker BioMarine ASA is pleased to announce that Carl Christian Bachke has been appointed SVP Investor Relations effective from 1 October 2021.

Bachke has a broad experience from and understanding of the Norwegian capital market. For the last eight years, he has been partner and senior adviser in the leading Norwegian capital market and IR firm Crux Advisers, where he has served as adviser for large- and medium-sized companies, both as listed entities and in IPO processes. Prior to that, Bachke held senior equity analyst positions in Nordea Markets, RS Platou Markets and Fondsfinans, with focus on oil, energy and industrial segments. Bachke started his professional career in Norsk Hydro, among other as Investor Relations. He holds sivøk and CFA (AFA) degrees from NHH Norwegian School of Economics.

“I am looking forward to join the strong team at Aker BioMarine and contribute to its mission of improving human and planetary health. The company has embarked on an exciting growth journey as the world’s leading supplier of krill nutrients, and capital markets play an important part of fulfilling the ambitions. In an open dialogue with the finance community, Aker BioMarine’s investor relations shall provide the relevant information at the right time”, Bachke comments.

As SVP Investor Relations, Bachke will report to Katrine Klaveness, CFO in Aker BioMarine.

“We are excited to welcome Carl Christian to Aker BioMarine. It is important to get our story and ambitions effectively across to all stakeholders, and to build a strong relationship with existing and potential shareholders. Carl Christian has extensive experience in investor- and market communication and will be central in this work” says Klaveness.

About Aker BioMarine

AkerBioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. Listed on Oslo Stock Exchange, the company develops krill-based ingredients for pharmaceutical, nutraceutical (Superba®), aquaculture (QRILL®Aqua), and animal feed applications (QRILL®Pet), including INVI™, a highly concentrated protein isolate, and LYSOVETA™, a targeted transporter of EPA and DHA from krill. Aker BioMarine’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and to customers around the world. The company’s strong focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste. For further information go to www.akerbiomarine.com